INTERVENTION 1:	Intervention	0
Green Tea Extract	Intervention	1
extract	BAO:0003070	10-17
Green tea extract (GTE) supplement: Two green tea extract capsules twice daily after breakfast and dinner for one year. GTE was a decaffeinated green tea extract, and each capsule contained a total of 328.8 ± 28.9 mg catechins including 210.7 ± 11.0 mg of EGCG.	Intervention	2
extract	BAO:0003070	10-17
extract	BAO:0003070	50-57
extract	BAO:0003070	154-161
year	UO:0000036	114-118
capsule	GO:0042603	58-65
capsule	GO:0042603	172-179
INTERVENTION 2:	Intervention	3
Sugar Pill	Intervention	4
Placebo: Two placebo capsules twice daily after breakfast and dinner for one year. Placebo capsules contained maltodextrin, cellulose, and magnesium stearate.	Intervention	5
year	UO:0000036	77-81
maltodextrin	CHEBI:25140	110-122
Inclusion Criteria:	Eligibility	0
Signed informed consent	Eligibility	1
Healthy postmenopausal women aged 50-70 years	Eligibility	2
healthy	HP:0032322	0-7
"Heterogeneously dense" (51-75% glandular) or "extremely dense" (>75%glandular) breasts	Eligibility	3
Willing to avoid consumption of green tea for 1 year	Eligibility	4
year	UO:0000036	48-52
Exclusion Criteria:	Eligibility	5
Positive serological markers of hepatitis B or hepatitis C infections	Eligibility	6
hepatitis b	DOID:2043	32-43
hepatitis c	DOID:1883	47-58
Elevated levels of liver enzymes	Eligibility	7
liver	UBERON:0002107	19-24
Recent (within 6 mo) or current hormone or hormone modification therapy, including systemic hormone replacement therapy, SERMS and aromatase inhibitors	Eligibility	8
hormone	CHEBI:24621	32-39
hormone	CHEBI:24621	43-50
hormone	CHEBI:24621	92-99
Current smoker of cigarettes or other tobacco products	Eligibility	9
BMI <19 or >40 kg/m2	Eligibility	10
Weight change > 10 lbs during the previous year	Eligibility	11
year	UO:0000036	43-47
History of breast cancer or proliferative breast disease	Eligibility	12
history	BFO:0000182	0-7
breast cancer	DOID:1612	11-24
breast disease	DOID:3463	42-56
Regular consumption of > 7 alcoholic drinks/wk	Eligibility	13
Regular consumption of green tea (>1 cup/wk)	Eligibility	14
Recent (within 6 mo) or current use of chemopreventive agents such as tamoxifen, raloxifene or aromatase inhibitors	Eligibility	15
tamoxifen	CHEBI:41774	70-79
raloxifene	CHEBI:8772	81-91
Participation in any weight loss or weight gain studies	Eligibility	16
weight loss	HP:0001824	21-32
Currently taking Methotrexate or Enbrel	Eligibility	17
methotrexate	CHEBI:44185	17-29
History of ovarian cancer	Eligibility	18
history	BFO:0000182	0-7
ovarian cancer	DOID:2394	11-25
Any form of cancer in the last 5 years	Eligibility	19
cancer	DOID:162	12-18
Presence of implants	Eligibility	20
Outcome Measurement:	Results	0
Mammographic Density	Results	1
Percent mammographic density was measured on digital images using a computer-assisted and quantitative method.	Results	2
percent	UO:0000187	0-7
Time frame: Baseline and month 12	Results	3
time	PATO:0000165	0-4
month	UO:0000035	25-30
Results 1:	Results	4
Arm/Group Title: Green Tea Extract	Results	5
extract	BAO:0003070	27-34
Arm/Group Description: Green tea extract (GTE) supplement: Two green tea extract capsules twice daily after breakfast and dinner for one year. GTE was a decaffeinated green tea extract, and each capsule contained a total of 328.8   28.9 mg catechins including 210.7   11.0 mg of EGCG.	Results	6
extract	BAO:0003070	33-40
extract	BAO:0003070	73-80
extract	BAO:0003070	177-184
year	UO:0000036	137-141
capsule	GO:0042603	81-88
capsule	GO:0042603	195-202
Overall Number of Participants Analyzed: 462	Results	7
Geometric Mean (95% Confidence Interval)	Results	8
mean	BAO:0002173	10-14
Unit of Measure: Percent  Percent mammographic density at baseline: 22.71        (21.39 to 24.10)	Results	9
percent	UO:0000187	17-24
percent	UO:0000187	26-33
Percent mammographic density at month 12: 22.09        (20.77 to 23.50)	Results	10
percent	UO:0000187	0-7
month	UO:0000035	32-37
Results 2:	Results	11
Arm/Group Title: Sugar Pill	Results	12
Arm/Group Description: Placebo: Two placebo capsules twice daily after breakfast and dinner for one year. Placebo capsules contained maltodextrin, cellulose, and magnesium stearate.	Results	13
year	UO:0000036	100-104
maltodextrin	CHEBI:25140	133-145
Overall Number of Participants Analyzed: 470	Results	14
Geometric Mean (95% Confidence Interval)	Results	15
mean	BAO:0002173	10-14
Unit of Measure: Percent  Percent mammographic density at baseline: 21.84        (20.59 to 23.17)	Results	16
percent	UO:0000187	17-24
percent	UO:0000187	26-33
Percent mammographic density at month 12: 21.13        (19.88 to 22.47)	Results	17
percent	UO:0000187	0-7
month	UO:0000035	32-37
Adverse Events 1:	Adverse Events	0
Total: 12/538 (2.23%)	Adverse Events	1
Hypertension 0/538 (0.00%)	Adverse Events	2
hypertension	HP:0000822,DOID:10763	0-12
Acoustic Neuroma 1/538 (0.19%)	Adverse Events	3
acoustic neuroma	DOID:12689	0-16
Diarrhea 0/538 (0.00%)	Adverse Events	4
diarrhea	HP:0002014,DOID:13250	0-8
Colitis 1/538 (0.19%)	Adverse Events	5
colitis	HP:0002583,DOID:0060180	0-7
Elevated ALT or AST enzyme 7/538 (1.30%)	Adverse Events	6
enzyme	BAO:0000279	20-26
Diagnosis of Uterine Cancer 0/538 (0.00%)	Adverse Events	7
uterine cancer	DOID:363	13-27
Motorcycle accident 0/538 (0.00%)	Adverse Events	8
Fall 0/538 (0.00%)	Adverse Events	9
Surgery 3/538 (0.56%)	Adverse Events	10
surgery	OAE:0000067	0-7
Adverse Events 2:	Adverse Events	11
Total: 8/537 (1.49%)	Adverse Events	12
Hypertension 1/537 (0.19%)	Adverse Events	13
hypertension	HP:0000822,DOID:10763	0-12
Acoustic Neuroma 0/537 (0.00%)	Adverse Events	14
acoustic neuroma	DOID:12689	0-16
Diarrhea 1/537 (0.19%)	Adverse Events	15
diarrhea	HP:0002014,DOID:13250	0-8
Colitis 0/537 (0.00%)	Adverse Events	16
colitis	HP:0002583,DOID:0060180	0-7
Elevated ALT or AST enzyme 0/537 (0.00%)	Adverse Events	17
enzyme	BAO:0000279	20-26
Diagnosis of Uterine Cancer 2/537 (0.37%)	Adverse Events	18
uterine cancer	DOID:363	13-27
Motorcycle accident 1/537 (0.19%)	Adverse Events	19
Fall 1/537 (0.19%)	Adverse Events	20
Surgery 2/537 (0.37%)	Adverse Events	21
surgery	OAE:0000067	0-7
